323 related articles for article (PubMed ID: 22516388)
1. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
3. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
[TBL] [Abstract][Full Text] [Related]
4. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
6. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
8. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
9. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
10. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
11. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
13. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
15. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
17. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
18. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT.
Albuquerque K; Giangreco D; Morrison C; Siddiqui M; Sinacore J; Potkul R; Roeske J
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1043-7. PubMed ID: 20471182
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of clinical efficacy of intensity-modulated radiation therapy and the prognosis factors in advanced cervical cancer].
Gao K; Ding L; Li L
Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):30-5. PubMed ID: 24694915
[TBL] [Abstract][Full Text] [Related]
20. Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?
Xu B; Guo Y; Chen Y; Lu H; Tang T; Yue Z; Guan G; Chi P; Lin C
Radiat Oncol; 2015 Dec; 10():257. PubMed ID: 26684643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
